UAE Approves Foundayo: A Breakthrough in Weight Loss Solutions

The United Arab Emirates has taken a significant step in healthcare by approving Foundayo (orforglipron), a once-daily oral obesity pill developed by Eli Lilly. This development positions the UAE among the first countries globally to offer a needle-free option for weight loss, diverging from traditional injectable treatments.

Understanding the Importance of Foundayo

As obesity is increasingly associated with severe long-term health conditions—such as Type 2 diabetes, cardiovascular diseases, and certain cancers—Foundayo’s introduction provides a more user-friendly option. Unlike GLP-1 injectable medications, this new pill offers a simpler regimen for patients, eliminating strict meal or water timing requirements.

Targeted Usage of Foundayo

It’s crucial to note that Foundayo is not intended for casual use. The medication will only be prescribed under strict medical supervision. Physicians across the UAE will utilize comprehensive eligibility guidelines to determine which patients may benefit from this new treatment. Typically, patients must have a body mass index (BMI) of 30 or above, or a BMI over 27 with associated health conditions, such as:

• Diabetes
• Hypertension
• High cholesterol
• Sleep apnea
• Joint stress conditions

Before starting treatment, patients will undergo thorough medical assessments, including blood tests, metabolic screenings, and a complete review of their medical history. Specialists, including endocrinologists and internal medicine experts, will guide the appropriateness of this medication to ensure targeted and justified use.

How Foundayo Promotes Weight Loss

Foundayo belongs to the class of medications known as GLP-1 receptor agonists, which simulate natural hormones that regulate appetite and blood sugar. The medication helps patients feel full sooner and reduces hunger signals, leading to a decrease in calorie intake without imposing severe dietary restrictions.

Clinical Efficacy of Foundayo

Clinical trials have demonstrated impressive results, with patients using higher doses averaging a weight loss of up to 12.4%. Some reports suggest weight reductions of around 12 kilograms within a 72-week span. Aside from weight loss, findings indicate potential improvements in cholesterol levels and blood pressure, highlighting broader metabolic benefits. However, side effects, particularly during the initial treatment stages, may include nausea and gastrointestinal discomfort, emphasizing the need for medical oversight.

Availability Timeline in the UAE

Foundayo is anticipated to be available in UAE pharmacies starting May 2026, although it will be accessible only through prescriptions. It is essential to understand that Foundayo is not a quick-fix solution; it should be part of a comprehensive long-term weight management plan. Patients may need to remain on this medication for extended durations—sometimes for life—depending on individual health conditions.

Moreover, discontinuing the medication without maintaining lifestyle modifications, such as a balanced diet and regular exercise, could lead to weight regain. Specific medical exclusions will apply, as Foundayo is not recommended for pregnant or breastfeeding women and may be unsuitable for individuals with certain thyroid cancers or severe gastrointestinal and kidney issues.

Expected Pricing of Foundayo

While the official pricing for Foundayo in the UAE has yet to be disclosed, early estimates suggest it could fall within the price range of existing GLP-1 treatments. Currently, injectable alternatives in the UAE average between Dh800 and Dh1,500 per month. Experts anticipate that Foundayo will be competitively priced; however, its oral format may affect the final cost based on demand and insurance coverage.

Ensuring Patient Safety with Foundayo

UAE regulators have emphasized that the approval of Foundayo represents a controlled medical advancement rather than a general weight-loss remedy. The Emirates Drug Establishment conducted an extensive scientific review of the drug’s safety and effectiveness, aligning it with the country’s strategy to combat rising obesity rates.

Dr. Fatima Al Kaabi, the Director-General of the authority, stressed the need to address obesity due to its links to over 200 diseases, affirming that the approval signifies a shift toward more patient-friendly therapies. Medical professionals echo these concerns, noting potential mild-to-moderate gastrointestinal side effects associated with GLP-1 receptor agonists, especially during the initial treatment phases.

UAE authorities are committed to ensuring that advances in treatment go hand-in-hand with patient safety while broadening access to effective weight management solutions.

Note: The information provided in this article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new medication or treatment.